moxifloxacin has been researched along with Disease Exacerbation in 15 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (6.67) | 29.6817 |
| 2010's | 13 (86.67) | 24.3611 |
| 2020's | 1 (6.67) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, Y; Li, Z; Meng, W; Xiong, R; Zeng, H; Zhao, Z | 1 |
| Li, HQ; Ning, W; Wang, JX; Zhang, F | 1 |
| Carrera-Pineda, R; Garcia-Luna, RC; Soto-Cabrera, E; Villamil-Osorio, LV | 1 |
| Herath, SC; Maisey, S; Normansell, R; Poole, P | 1 |
| Chatzika, K; Kioumis, I; Kontou, P; Manika, K; Pitsiou, G; Sionidou, M; Zarogoulidis, P | 1 |
| Diethelm, M; Schuster, S | 1 |
| Herath, SC; Poole, P | 1 |
| Amoroso, A; Britt, EJ; Burke, AP; Franco, M; Reed, RM | 1 |
| Anzueto, A; Arvis, P; Haverstock, D; Miravitlles, M; Sethi, S; Trajanovic, M; Wilson, R | 1 |
| England, BS; Twilla, JD; Van Berkel, MA | 1 |
| Bang, ES; Kim, H; Lee, JM; Lim, SK | 1 |
| Carlson, EM; Meskin, SW | 1 |
| Arvis, P; Choudhri, SH; Haverstock, D; Kruesmann, F; Miravitlles, M; Perroncel, R | 1 |
| Hu, Y; Shen, K; Shen, Y; Zhang, J | 1 |
| Ader, F; Bernard, L; Carlier, R; Perronne, C; Salomon, J; Toubiana, J | 1 |
5 review(s) available for moxifloxacin and Disease Exacerbation
| Article | Year |
|---|---|
Prophylactic antibiotic therapy for chronic obstructive pulmonary disease (COPD).
Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Antibiotic Prophylaxis; Aza Compounds; Azithromycin; Clarithromycin; Clavulanic Acid; Disease Progression; Drug Administration Schedule; Erythromycin; Fluoroquinolones; Humans; Moxifloxacin; Pulmonary Disease, Chronic Obstructive; Quality of Life; Quinolines; Randomized Controlled Trials as Topic; Roxithromycin; Trimethoprim, Sulfamethoxazole Drug Combination | 2018 |
Prophylactic antibiotic therapy for chronic obstructive pulmonary disease (COPD).
Topics: Aged; Anti-Bacterial Agents; Antibiotic Prophylaxis; Aza Compounds; Azithromycin; Clarithromycin; Disease Progression; Erythromycin; Fluoroquinolones; Humans; Moxifloxacin; Pulmonary Disease, Chronic Obstructive; Quality of Life; Quinolines; Randomized Controlled Trials as Topic | 2013 |
Emergency Department Management of a Myasthenia Gravis Patient with Community-Acquired Pneumonia: Does Initial Antibiotic Choice Lead to Cure or Crisis?
Topics: Aged, 80 and over; Anti-Bacterial Agents; Community-Acquired Infections; Disease Progression; Female; Fluoroquinolones; Humans; Minocycline; Moxifloxacin; Myasthenia Gravis; Pneumonia; Tigecycline | 2016 |
Mooren's-type ulceration associated with severe hidradenitis suppurativa: a case report and literature review.
Topics: Amnion; Antibodies, Monoclonal; Aza Compounds; Conjunctiva; Corneal Perforation; Corneal Ulcer; Dermatologic Agents; Disease Progression; Doxycycline; Drug Therapy, Combination; Fluoroquinolones; Hidradenitis Suppurativa; Humans; Immunosuppressive Agents; Infliximab; Male; Methotrexate; Middle Aged; Moxifloxacin; Prednisolone; Prednisone; Quinolines; Severity of Illness Index; Treatment Outcome; Visual Acuity | 2011 |
Sputum colour and bacteria in chronic bronchitis exacerbations: a pooled analysis.
Topics: Anti-Bacterial Agents; Aza Compounds; Bacteria; Bronchitis, Chronic; Color; Disease Progression; Dyspnea; Female; Fluoroquinolones; Gentian Violet; Humans; Male; Moxifloxacin; Multicenter Studies as Topic; Phenazines; Pneumonia, Bacterial; Quinolines; Randomized Controlled Trials as Topic; Sex Factors; Sputum | 2012 |
2 trial(s) available for moxifloxacin and Disease Exacerbation
| Article | Year |
|---|---|
Systemic inflammation and the effects of short-term antibiotic treatment for PPM positive patients with stable COPD.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Bacteria; Bacterial Infections; China; Disease Progression; Drug Administration Schedule; Female; Humans; Inflammation Mediators; Male; Middle Aged; Moxifloxacin; Pulmonary Disease, Chronic Obstructive; Respiratory Tract Infections; Risk Factors; Sputum; Time Factors; Treatment Outcome | 2019 |
Prognostic factors for clinical failure of exacerbations in elderly outpatients with moderate-to-severe COPD.
Topics: Age Factors; Aged; Ambulatory Care; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Chi-Square Distribution; Disease Progression; Double-Blind Method; Female; Fluoroquinolones; Forced Expiratory Volume; Humans; Logistic Models; Lung; Male; Middle Aged; Moxifloxacin; Multivariate Analysis; Prospective Studies; Pulmonary Disease, Chronic Obstructive; Risk Factors; Severity of Illness Index; Sputum; Time Factors; Treatment Failure | 2015 |
8 other study(ies) available for moxifloxacin and Disease Exacerbation
| Article | Year |
|---|---|
Nemonoxacin achieved a better symptomatic improvement and a prolonged interval to next exacerbation than moxifloxacin for outpatients with acute exacerbations of chronic obstructive pulmonary disease.
Topics: Anti-Bacterial Agents; Disease Progression; Humans; Moxifloxacin; Outpatients; Pulmonary Disease, Chronic Obstructive | 2023 |
[Optochiasmatic tuberculomas as a paradoxical reaction to treatment for meningeal tuberculosis].
Topics: Adult; Antitubercular Agents; Brain Infarction; Diagnostic Errors; Disease Progression; Drug Resistance, Microbial; Drug Substitution; Ethambutol; Female; Host-Pathogen Interactions; Humans; Isoniazid; Magnetic Resonance Imaging; Meningitis, Viral; Moxifloxacin; Mycobacterium tuberculosis; Neuroimaging; Optic Chiasm; Paresis; Prednisone; Pyrazinamide; Rifampin; Thalamus; Tuberculoma; Tuberculosis, Meningeal; Vision Disorders | 2018 |
Moxifloxacin in Chronic Obstructive Pulmonary Disease: Pharmacokinetics and Penetration into Bronchial Secretions in Ward and Intensive Care Unit Patients.
Topics: Aged; Anti-Bacterial Agents; Bacterial Infections; Critical Care; Disease Progression; Female; Humans; Intensive Care Units; Male; Microbial Sensitivity Tests; Moxifloxacin; Prospective Studies; Pulmonary Disease, Chronic Obstructive | 2019 |
[Achilles heel of COPD].
Topics: Achilles Tendon; Aged; Anti-Bacterial Agents; Anti-Inflammatory Agents; Aza Compounds; Diagnosis, Differential; Disease Progression; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyspnea; Fluoroquinolones; Humans; Male; Mobility Limitation; Moxifloxacin; Ofloxacin; Prednisone; Pulmonary Disease, Chronic Obstructive; Quinolines; Respiratory Insufficiency; Rupture, Spontaneous; Ultrasonography | 2013 |
Pulmonary mycobacterial spindle cell pseudotumor in a lung transplant patient: progression without therapy and response to therapy.
Topics: Aged; Anti-Bacterial Agents; Azithromycin; Disease Progression; Ethambutol; Female; Fluoroquinolones; Humans; Immunocompromised Host; Lung; Lung Transplantation; Moxifloxacin; Mycobacterium avium Complex; Mycobacterium avium-intracellulare Infection; Treatment Outcome | 2015 |
DRESS syndrome and acute generalized exanthematous pustulosis induced by antituberculosis medications and moxifloxacin: case report
.
Topics: Acute Generalized Exanthematous Pustulosis; Adult; Antitubercular Agents; Disease Progression; Drug Hypersensitivity Syndrome; Eosinophils; Female; Fluoroquinolones; Humans; Moxifloxacin; Pruritus | 2016 |
Combination therapy with immune-modulators and moxifloxacin on fulminant macrolide-resistant Mycoplasma pneumoniae infection: A case report.
Topics: Anti-Bacterial Agents; Aza Compounds; Child; Disease Progression; Drug Therapy, Combination; Fluoroquinolones; Glucocorticoids; Humans; Immunoglobulins, Intravenous; Male; Methylprednisolone; Moxifloxacin; Pneumonia, Mycoplasma; Pulse Therapy, Drug; Quinolines | 2013 |
[Cervical spondylodiscitis: one pathogen may hide another].
Topics: Anti-Bacterial Agents; Antitubercular Agents; Aza Compounds; Cervical Vertebrae; Cholecystitis; Discitis; Disease Progression; Drug Therapy, Combination; Escherichia coli; Escherichia coli Infections; Ethambutol; Fluoroquinolones; France; Humans; Immobilization; Isoniazid; Male; Middle Aged; Morocco; Moxifloxacin; Mycobacterium tuberculosis; Pyrazinamide; Quinolines; Radiography; Rifampin; Tuberculosis, Spinal | 2006 |